Freedom Capital Upgrades Abbott Laboratories (ABT) to Buy

​Abbott Laboratories (NYSE:ABT) is one of the Best 52-Week Low Stocks to Invest In. On January 29, Freedom Capital upgraded the stock from Hold to Buy, but lowered the price target from $130 to $120. Earlier, on January 23, UBS reiterated a Buy rating on the stock with a $158 price target.

​The positive ratings come despite the company missing revenue estimates for its fiscal Q4 2025 earnings, released on January 22. The company grew its revenue by 4.24% year-over-year to $11.46 billion, but fell short of the consensus by $342.91 million. The EPS of $1.50 topped expectations by $0.01.

​The analysts at Freedom Capital noted that the weak results were mainly due to the weakness in the company’s Nutrition segment. The firm noted that management expects this weakness to persist throughout the first half of 2026. However, the Medical Devices and Established Pharma segment of Abbott Laboratories (NYSE:ABT) continues to be the key driver of growth and is offsetting challenges in other segments.

​Freedom Capital remains optimistic on the company’s future growth prospects, driven by the integration of Exact Sciences in Q2. The firm finds the company’s 6.5% to 7.5% organic revenue growth guidance for 2026 to be conservative.

​Abbott Laboratories (NYSE:ABT) is a global healthcare company with a broad portfolio spanning diagnostics, medical devices, nutrition, and branded generic medicines.

While we acknowledge the potential of ABT to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ABT and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.